Online inquiry

IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3865MR)

This product GTTS-WQ3865MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3865MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2346MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ4130MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ15454MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ15585MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ13412MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ11088MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ15720MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ7456MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW